Policy & Regulation
Datroway approved in EU for first-line metastatic triple-negative breast cancer
31 July 2026 - Datroway (datopotamab deruxtecan), jointly developed by Japanese healthcare company Daiichi Sankyo Co Ltd (TYO:4568) and British-Swedish biopharmaceutical company AstraZeneca plc (STO:A...
Karyopharm reports topline Phase 3 trial results in endometrial cancer
31 July 2026 - Karyopharm Therapeutics Inc (Nasdaq:KPTI), a commercial-stage pharmaceutical company developing novel cancer therapies, on Thursday announced topline results from its Phase 3 XPORT-EC-0...
Kaigene and Taisho enter exclusive KG006 licensing agreement in Japan
31 July 2026 - US-based biotechnology company Kaigene Inc announced on Thursday that it has entered into an exclusive licensing agreement with Japanese pharmaceutical company Taisho Pharmaceutical Co ...
Pfizer reports positive Phase 3 results for LITFULO in nonsegmental vitiligo
30 July 2026 - US biopharmaceutical company Pfizer Inc (NYSE:PFE) on Thursday announced positive topline results from two Phase 3 trials evaluating LITFULO (ritlecitinib) as a potential oral systemic ...
Octapharma to build USD1.5bn critical care manufacturing facility in Rock Hill, SC
30 July 2026 - Switzerland-based plasma fractionator Octapharma on Wednesday announced plans to establish its first-ever US-based manufacturing and production site at the Palmetto Research Park in Roc...
Ractigen Therapeutics closes over USD31m financing for project advancement
30 July 2026 - Ractigen Therapeutics, a clinical-stage biotechnology company developing small activating RNA (saRNA) therapeutics and advanced extrahepatic delivery systems, announced on Wednesday the...